Metoclopramide in Upper Gastrointestinal Bleed

Description

The goal of this clinical trial is to test if metoclopramide can improve effectiveness of endoscopic intervention in upper gastrointestinal (GI) bleeds. The main questions the investigators hope to answer is Does metoclopramide lessen the need for repeat endoscopy, interventional radiology intervention or surgery in cases of upper GI bleed? Does metoclopramide improve visibility of the GI walls in cases of upper GI bleed?

Conditions

Upper GI Bleeding, Bleeds Gastric, Bleed Ulcer, Hemorrhage Gastric, Hemorrhage; Ulcer

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this clinical trial is to test if metoclopramide can improve effectiveness of endoscopic intervention in upper gastrointestinal (GI) bleeds. The main questions the investigators hope to answer is Does metoclopramide lessen the need for repeat endoscopy, interventional radiology intervention or surgery in cases of upper GI bleed? Does metoclopramide improve visibility of the GI walls in cases of upper GI bleed?

Premedication With Metoclopramide in Upper Gastrointestinal Bleeds a Prospective Double Blinded Single Center Randomized Control Trial in a Small Community Hospital

Metoclopramide in Upper Gastrointestinal Bleed

Condition
Upper GI Bleeding
Intervention / Treatment

-

Contacts and Locations

Rockford

Javon Bea Hospital-Riverside - MercyHealth, Rockford, Illinois, United States, 61114

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18 and above
  • * Admitted to ER or inpatient services at Javon Bea Hospital MercyHealth Riverside
  • * Present with upper GI bleeding defined as fresh and bright red hematemesis, coffee-ground hematemesis or melena
  • * Plan to undergo EGD within 24 hours since admission or since first symptoms
  • * Calculated Glasgow-Blatchford score ≥ 2
  • * Failure to obtain informed consent
  • * Known allergy to metoclopramide
  • * Concurrent use of medications known to cause tardive dyskinesia (TD)/extrapyramidal symptoms/neuroleptic malignant syndrome
  • * History of TD or dystonic reaction to metoclopramide
  • * Pheochromocytoma, catecholamine-releasing paragangliomas
  • * Parkinson's Disease
  • * Epilepsy
  • * Pregnancy or lactation
  • * Previous gastrectomy

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Mercy Health System,

Study Record Dates

2024-06